Market Cap 5.26B
Revenue (ttm) 739.02M
Net Income (ttm) -436.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -59.05%
Debt to Equity Ratio -8.18
Volume 1,287,100
Avg Vol 2,301,206
Day's Range N/A - N/A
Shares Out 123.42M
Stochastic %K 38%
Beta 1.50
Analysts Strong Sell
Price Target $53.33

Latest News on GH

Guardant Health, Inc. (GH) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 11:14 PM EST - 5 weeks ago

Guardant Health, Inc. (GH) Q4 2024 Earnings Call Transcript


Guardant Health to Participate in Upcoming Investor Conferences

Feb 10, 2025, 7:00 AM EST - 7 weeks ago

Guardant Health to Participate in Upcoming Investor Conferences


Guardant Health Announces Debt Exchange Transactions

Feb 7, 2025, 6:30 AM EST - 7 weeks ago

Guardant Health Announces Debt Exchange Transactions


Guardant Health Stock Flashing Surefire ‘Buy' Signal

Dec 4, 2024, 1:31 PM EST - 4 months ago

Guardant Health Stock Flashing Surefire ‘Buy' Signal


Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 9:53 PM EST - 5 months ago

Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript


Roberto A. Mignone Joins Guardant Health Board of Directors

Oct 24, 2024, 5:05 PM EDT - 5 months ago

Roberto A. Mignone Joins Guardant Health Board of Directors


Guardant Health, Inc. (GH) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 11:59 PM EDT - 8 months ago

Guardant Health, Inc. (GH) Q2 2024 Earnings Call Transcript


Guardant Health Gets FDA Nod on Colorectal Cancer Blood Test

Jul 29, 2024, 2:57 PM EDT - 8 months ago

Guardant Health Gets FDA Nod on Colorectal Cancer Blood Test


US FDA approves Guardant Health's blood-based cancer test

Jul 29, 2024, 6:41 AM EDT - 8 months ago

US FDA approves Guardant Health's blood-based cancer test